This journal is a member of and subscribes to the principles of the Committee on Publication Ethics. Journal Citation Score*:1.56. Article influence score*:3.819 Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ. From magazine subscription chock-full of supportive and easy-to-read articles for cancer patients, and families to books to inspire, this section includes can't-miss free books, magazines, printed organizers, and care journals designed specially to support the needs of cancer patients, caregivers, and families. Recent studies have suggested that patients with ETP-ALL and Ph-like ALL be treated as high-risk and be offered Allo-SCT during CR1 as well.161, 162 The role of Allo-SCT in standard-risk adults is less clearly defined. Here, we review the major recent advances in the treatment of ALL. XX. Join the Blood Cancer Journal Twitter Community. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Preclinical studies have suggested a role for RNA-based methods with multiple infusions; however, all current clinical trials utilize a viral vector to deliver the CAR construct.150, As mentioned above, CD19 is an ideal target for immunotherapy against B-cell ALL due to its near universal expression on B-lymphoblasts. The Anti-CD19 AntibodyDrug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia. The structure of treatment of adult ALL has been adapted from pediatric protocols. Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS) Meldola, Italy. Elderly patients are often unable to tolerate such regimens and carry a particularly poor prognosis. Common symptoms include B symptoms (fever, weight loss, night sweats), easy bleeding or bruising, fatigue, dyspnea and infection. Associate Editor. Year. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. You are using a browser version with limited support for CSS. Use of vincristine and prednisone alone. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. In pediatric patients with relapsed/refractory ALL, combotox led to a CR in 3 of 17 patients. Pediatric Blood & Cancer ( PBC ), published monthly ( online only) by Wiley-Blackwell, is the official journal of the International Society of Pediatric Oncology (SIOP) and ASPHO. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. When used in combination with a chemotherapy regimen that mimicked pediatric induction protocols, SAR3419 was effective at prolonging the duration of remission.117 SAR3419 was then evaluated in a Phase 1 clinical trial with CD19+ B-cell lymphoma. The first attempt at classifying ALL was the French American British (FAB) morphological criteria that divided ALL into 3 subtypes (L1, L2 and L3) based on cell size, cytoplasm, nucleoli, vacuolation and basophilia.18 In 1997, the World Health Organization proposed a composite classification in attempt to account for morphology and cytogenetic profile of the leukemic blasts and identified three types of ALL: B lymphoblastic, T lymphoblastic and Burkitt-cell Leukemia.19 Later revised in 2008, Burkitt-cell Leukemia was eliminated as it is no longer seen as a separate entity from Burkitt Lymphoma, and B-lymphoblastic leukemia was divided into two subtypes: B-ALL with recurrent genetic abnormalities and B-ALL not otherwise specified. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaresults of the prospective multicenter LALA-94 trial. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W et al. The rate of complete remission was 31% (95% CI, 17, 48%), the median DFS and OS were 20 weeks with a 1-year OS of 28%.77 However, there is still more that needs to be done to achieve a better response and overall survival in patients with relapsed/refractory B- and T-cell ALL. Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA et al. Another novel anti-CD20 monoclonal antibody, obinutuzumab, has shown promise in preclinical trials for CD20-positive B-ALL. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. However, with the development of TKIs, survival has improved and thus the Ph-status of all patients must be obtained prior to starting therapy. blood cancer journal for authors & referees guide to authors Guide to Authors Article Type Specifications Article: An Article is a substantial, in-depth, novel research study of interest. Feasibility Of pegylated-asparaginase (PEG-ASP) during induction in adults with acute lymphoblastic leukaemia (ALL): results from the UK Phase 3 Multicentre Trial UKALL 14. Dongen JJMv, v.d. Brakel J, Pluyter M, Huang H et al. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Current concepts in the diagnosis and management of cytokine release syndrome. Twelve patients were bridged to Allo-SCT, with five long-term survivors.69 This study led to the accelerated approval of VSLI for salvage therapy in 2012. A peer-reviewed online open access journal seeking to publish articles of the highest quality related to hematologic malignancies and related disorders. Subsequently, other studies163 evaluated the risk factors in patients treated with Allo-SCT versus standard chemotherapy after CR1. Welcome to Blood Cancer Journal A peer-reviewed online open access journal seeking to publish articles of the highest quality related to hematologic malignancies and related disorders. DNA methylation is an important epigenetic modification that regulates gene expression. The 15 patients in which CRS was severe were effectively treated with the anti-IL-6-receptor antibody, tocilizumab.152 Important causes of treatment failure included the loss of circulating CAR-Ts and the expansion of a CD19-negative clone. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE et al. 1New York University School of Medicine, New York, USA, 2Department of Hematology, New York University Perlmutter Cancer Center, New York, USA. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? The Journal will consider for publication original research, reviews, guidelines and letters that are considered to be of high impact in the field. Recently, it has become standard practice to evaluate patients for minimal residual disease (MRD) using molecular techniques such as flow cytometry and PCR.28 Several studies have shown the importance of MRD in assigning risk.29, 30, 31, 32, 33, 34 Bruggemann et al.29 re-stratified standard-risk patients to low risk, intermediate risk and high risk with relapse rates of 0%, 47% and 94%, respectively, based on the persistence of elevated MRD, defined as >104. Outcome of Adults With Acute Lymphocytic Leukemia After Second Salvage Therapy. In a prospective study, Stock et al.64 treated 317 patients aged 1739 on Childrens Oncology Group AALL0232 protocol. 2018 Volume 8; 2017 Volume 7; 2016 Volume 6; 2015 Volume 5; 2014 Volume 4; 2013 Volume 3; 2012 Volume 2; 2011 Volume 1; Explore content. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E et al. Cycles were repeated every 22 days. Outcome for Adolescent and Young Adults 1621 years of age (AYA) with Acute Lymphoblastic Leukemia (ALL) Treated on the Children s Cancer Group (CCG) 1961 Study. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al. Immunoconjugates, such as inotuzumab ozogamicin, bind to leukemic cells, are internalized and release a cytotoxin that kills the leukemic cell; whereas dual-specific antibodies, such as blinatumumab, cause the direct activation of T cells against blasts. Topics of particular interest include, but are not limited to, the following: Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways. 2013; Available at: http://meetinglibrary.asco.org/content/111816-132. In a phase 2 study, decitabine and vorinostat (a histone deacetylase inhibitor) were given prior to vincristine, prednisone, PEG-L-asparaginase and doxorubicin for relapsed/refractory ALL.139 Results were promising with a CR rate of 50% (95% CI, 15.784.3%) and the OR rate 75% (95% CI, 34.996.8%). Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S et al. Department of Leukemia, Houston, Texas, The biology and therapy of adult acute lymphoblastic leukemia. A CR was observed in 50 patients (94%), with a 12-month EFS rate of 45% (95% CI, 3166%) and OS rate of 78% (95% CI, 6791%). Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R et al. blood cancer journal research articles Research articles Article Type Year Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a. Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V et al. She was able to undergo Allo-SCT after CR was achieved with re-induction therapy and remained in CR 8 months after transplant.137 In a MD Anderson phase I trial of decitabine for relapsed/refractory ALL, decitabine was shown to have efficacy when used in combination with Hyper-CVAD for re-induction therapy.138 In addition, decitabine monotherapy is well tolerated and thus offers a potential treatment option for relapsed disease in patients that cannot tolerate multi-agent chemotherapy. In the meantime, to ensure continued support, we are displaying the site without styles Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, OBrien S et al. Subsequently, blinatumomab was compared to investigators choice of chemotherapy for r/r Ph-negative ALL in the phase 3 randomized trial (TOWER study). CR was observed in 36 and 88% of whom were MRD negative, and with a median follow-up of 9 months, the median OS was 7.1 months.75 Future investigation is planned for the frontline use of blinatumomab for Ph-positive ALL in conjunction with TKIs.76 The toxicity profile of blinatumomab is acceptable. and JavaScript. Nearly all of the patients developed cytokine release syndrome (CRS). Teeling JL, French RR, Cragg MS, v.d. Ofatumumab is a second-generation anti-CD20 antibody with a distinct binding site from that of rituximab. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. In addition, six additional patients experienced a >95% reduction in peripheral blasts.98 In adults with relapsed/refractory disease, combotox led to reduction of peripheral blasts in all patients; however, a durable response was not seen as blast count rebounded quickly after the final dose of combotox.99 A phase I trial is recruiting patients to evaluate combotox in combination with cytarabine for adults with relapsed/refractory ALL ({"type":"clinical-trial","attrs":{"text":"NCT01408160","term_id":"NCT01408160"}}NCT01408160). Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias. Thank you for visiting nature.com. Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and . Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. The prevalence of t(9;22) in adult ALL can range from 1550% and increases with age.24 Ph-positivity has implications both in terms of prognosis and for treatment. ISSN 2044-5385 (online), Cancel REGN1979 is a biallelic monoclonal antibody targeting CD20 and CD3. However, not all adults are able to tolerate such dose intensification and the exact subset of patients who are likely to benefit has not clearly been defined. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. However, with the ability to characterize the immunophenotype and genotype of each patients leukemia, targeted therapy can be expected to lead to improvements in remission and survival as part of individualized treatment strategies. In fact, in patients older than 45 years, there was a significantly higher rate of chemotherapy-related events compared to younger patients, suggesting that an age cutoff for pediatric-inspired regimens is appropriate. InO was given during each of the first four courses. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J et al. Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I et al. While 8590% of patients go into remission after induction therapy, there are subsets that are refractory to induction therapy. Fathi AT, Borate U, DeAngelo DJ, O'Brien MM, Trippett T, Shah BD et al. There is a waiver policy for these charges. Biological Abstracts Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Benzene is among the pollutants gas stoves emit into homes, Stanford University researchers show. CR was achieved after 2 cycles in 43 with 82% achieving MRD negativity. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Messinger YH, Gaynon PS, Sposto R, v.d. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G et al. PubMed/MEDLINE Faderl et al.66 treated 90 patients (median age 34) with relapsed or refractory disease with HCVAD in which the dosing of vincristine, dexamethasone and asparaginase where intensified as follows: vincristine 2mg i.v. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia, DNA Methylation as a Therapeutic Target in Cancer. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S et al. Chimeric antigen receptor-modified (CAR) T cells are genetically engineered T cells that express the antigen-binding domain of an immunoglobulin linked via transmembrane domains to the intracellular T-cell receptor signaling moieties.146 This allows the T cells to recognize unprocessed antigens and to be activated in a major histocompatibility complex (MHC)-independent manner. ISSN 2044-5385 (online), A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis, Cost comparison of post-remission strategies in younger and older AML patients in France, Outcomes in patients with chronic lymphocytic leukemia and, Monitoring measurable residual disease and chimerism in patients with, Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation, Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse, Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine, Integrated multi-omics analyses reveal homology-directed repair pathway as a unique dependency in near-haploid leukemia, Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience, Exercise-induced release of cardiac and skeletal muscle injury biomarkers in patients with chronic myeloid leukemia receiving TKI therapy, Should I stay or should I go (to transplant)? and JavaScript. Raff T, Gkbuget N, Lschen S, Reutzel R, Ritgen M, Irmer S et al. Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD et al. Traditionally, risk stratification has been based on clinical factors such age, white blood cell count and response to chemotherapy; however, the identification of recurrent genetic alterations has helped refine individual prognosis and guide management. The site is secure. Jabbour E, Hagop K, Thomas D, Garcia-Manero G, Hoehn D, Garris R et al. Acceptance of manuscripts is based on View full aims & scope Blood First Edition The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review, Multiple myeloma with acute light chain cast nephropathy, Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment, Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients, Featured article including author video summary, A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis, Cost comparison of post-remission strategies in younger and older AML patients in France, Outcomes in patients with chronic lymphocytic leukemia and, Monitoring measurable residual disease and chimerism in patients with, Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation, Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse, Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Read More About the Journal Editors-in-Chief Riccardo Dalla-Favera Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M et al. Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers, & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Clinical Cancer Research Molecular Cancer Research Sasaki K, Kantarjian HM, Ravandi F, Daver N, Kadia TM, Khouri RB et al. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. and JavaScript. Furthermore, elderly patients are particularly susceptible to the dose-limiting toxicities of these agents and are often excluded from Allo-SCT on the basis of performance status and medical comorbidities. Submissions are judged on how well the manuscript and described research fit the editorial scope of the journal and its expectations of scientific excellence, importance, and impact on the wider cancer research community. Blood Cancer Journal proudly publishes Current Treatment Algorithms, an article type dedicated to providing clear, authoritative, concise treatment pathways for hematologic malignancies. Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T. Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples, Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. CD22 is a B-lineage differentiation antigen expressed in B-cell ALL in 50100% of adults and 90% of children.78, 79, 80 Upon binding of an antibody, CD22 is rapidly internalized, thus making it an attractive target for delivering immunotoxin to leukemic cells.81, Epratuzumab is an unconjugated monoclonal antibody targeting CD22 that has been studied in pediatric and adult relapsed/refractory ALL.
Best Couples Golf Tournaments,
St Thomas More Bethel Park Mass Times,
Rent Room Switzerland,
Causes And Consequences Of Overpopulation,
Articles B
blood cancer journals
